Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study
- PMID: 25133871
 - PMCID: PMC4561502
 - DOI: 10.1001/jamapsychiatry.2014.1332
 
Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study
Abstract
Importance: Longitudinal studies have linked the systemic inflammatory markers interleukin 6 (IL-6) and C-reactive protein (CRP) with the risk of developing heart disease and diabetes mellitus, which are common comorbidities for depression and psychosis. Recent meta-analyses of cross-sectional studies have reported increased serum levels of these inflammatory markers in depression, first-episode psychosis, and acute psychotic relapse; however, the direction of the association has been unclear.
Objective: To test the hypothesis that higher serum levels of IL-6 and CRP in childhood would increase future risks for depression and psychosis.
Design, setting, and participants: The Avon Longitudinal Study of Parents and Children (ALSPAC)is a prospective general population birth cohort study based in Avon County, England. We have studied a subsample of approximately 4500 individuals from the cohort with data on childhood IL-6 and CRP levels and later psychiatric assessments.
Measurement of exposure: Levels of IL-6 and CRP were measured in nonfasting blood samples obtained in participants at age 9 years.
Main outcomes and measures: Participants were assessed at age 18 years. Depression was measured using the Clinical Interview Schedule-Revised (CIS-R) and Mood and Feelings Questionnaire (MFQ), thus allowing internal replication; psychotic experiences (PEs) and psychotic disorder were measured by a semistructured interview.
Results: After adjusting for sex, age, body mass index, ethnicity, social class, past psychological and behavioral problems, and maternal postpartum depression, participants in the top third of IL-6 values compared with the bottom third at age 9 years were more likely to be depressed (CIS-R) at age 18 years (adjusted odds ratio [OR], 1.55; 95% CI, 1.13-2.14). Results using the MFQ were similar. Risks of PEs and of psychotic disorder at age 18 years were also increased with higher IL-6 levels at baseline (adjusted OR, 1.81; 95% CI, 1.01-3.28; and adjusted OR, 2.40; 95% CI, 0.88-6.22, respectively). Higher IL-6 levels in childhood were associated with subsequent risks of depression and PEs in a dose-dependent manner.
Conclusions and relevance: Higher levels of the systemic inflammatory marker IL-6 in childhood are associated with an increased risk of developing depression and psychosis in young adulthood. Inflammatory pathways may provide important new intervention and prevention targets for these disorders. Inflammation might explain the high comorbidity between heart disease, diabetes mellitus, depression, and schizophrenia.
Figures
              
              
              
              
                
                
                References
- 
    
- Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448–457. - PubMed
 
 - 
    
- Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289(23):3095–3105. - PubMed
 
 - 
    
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. - PubMed
 
 - 
    
- Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53(11):1022–1031. - PubMed
 
 - 
    
- World Health Organization . The Global Burden of Disease: 2004 Update. World Health Organization; Geneva, Switzerland: 2008.
 
 
Publication types
MeSH terms
Substances
Grants and funding
- G0701503/MRC_/Medical Research Council/United Kingdom
 - G0001354/MRC_/Medical Research Council/United Kingdom
 - RP-PG-0606-1335/DH_/Department of Health/United Kingdom
 - 102215/WT_/Wellcome Trust/United Kingdom
 - MC_PC_15018/MRC_/Medical Research Council/United Kingdom
 
- 092731/WT_/Wellcome Trust/United Kingdom
 - G0801418/MRC_/Medical Research Council/United Kingdom
 - MR/L010305/1/MRC_/Medical Research Council/United Kingdom
 - G9815508/MRC_/Medical Research Council/United Kingdom
 - 084268/Z/07/Z/WT_/Wellcome Trust/United Kingdom
 - 095844/WT_/Wellcome Trust/United Kingdom
 - 088869/Z/09/Z/WT_/Wellcome Trust/United Kingdom
 - 095844/Z/11/Z/WT_/Wellcome Trust/United Kingdom
 
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
